Rabinowitz Matthew sold $448K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 1,718 shares of Natera, Inc. (NTRA) at $260.49 ($0.45M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not introduce new company performance information.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 structure suggests limited informational content.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or contract updates, the fundamental read-through is weak.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering a sale dated 2026-07-27.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. involving the executive chairman.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 1,718 shares in an open-market transaction on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 insider sale and explicitly notes a pre-arranged 10b5-1 plan, reducing signaling risk.

Market effects

Minimal. Insider sale disclosures rarely change sector fundamentals for diagnostics/oncology testing names.

None indicated.

None indicated.

Counterpoint

The sale is under a pre-arranged 10b5-1 plan, so it may reflect liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose executive chairman reported an open-market insider sale under a 10b5-1 plan.

  • Matthew Rabinowitz

    Executive Chairman and reporting person who sold 1,718 shares at $260.4908 on 2026-07-27.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.